Biomx AAQS

Mitä Biomx tekee? Biomx Inc, trading under the ticker PHGE, is a biotechnology company headquartered in Ness Ziona, Israel. The company focuses on developing bacteriophage-based therapies to address diseases caused by microbiome dysbiosis. Biomx Inc's approach combines natural and engineered phage solutions to target harmful bacteria affecting skin conditions and chronic diseases such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC), and cancer. The company identifies and validates bacterial targets, then customizes phage compositions to combat these targets. Biomx Inc's pipeline includes three product candidates: BX001, designed to improve acne-prone skin appearance; BX002, a customized phage cocktail targeting bacterial causes of IBD; and BX003, a phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp). Founded through an IPO on December 14, 2018, Biomx Inc employs approximately 20 people. The company operates within the health care sector, specifically in biotechnology, and is listed on financial markets under the ISIN US09090D5095. Biomx Inc is committed to advancing phage therapy as a novel treatment approach for microbiome-related disorders, with a focus on both therapeutic and preventive applications. The firm's research and development efforts aim to provide targeted solutions for complex bacterial interactions within the human microbiome. Biomx Inc's operations are based in Ness Ziona, Israel, and the company continues to develop its pipeline of phage-based treatments for various medical conditions. Biomx on yksi Eurpooliin suosituimmista yhtiöistä.